Company news

Prelude Therapeutics Incorporated (NASDAQ:PRLD) news

Every Prelude Therapeutics Incorporated press release and news update in one place — announcements, filings coverage, and company updates for investors.

Prelude Therapeutics Incorporated (NASDAQ:PRLD) news

Press releases & updates

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Sel...

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Hi...

Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 202...

Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhi...

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Prelude Therapeutics Announces Strategic Business Update

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

Prelude Announces Presentations at 2025 AACR Annual Meeting

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanu...

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Pat...

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Prelude Therapeutics Announces $25 Million Private Placement

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial ...

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

Prelude Therapeutics Announces Pricing of Public Offering

Prelude Therapeutics Announces Launch of Proposed Public Offering

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematolo...